Idera's GSOs and regulation of Neovascularization (in cardiac events)
This means we can open up a new indication in heart disease! On the 8/12/2014 CC, the CEO mentioned that this is a "transformational" technology that has potential to aid in the recovery process after cardiac events.
Effective neovascularization is crucial for recovery after cardiovascular events. In the study with Idera's GSOs, they were able to demonstrate that inhibition of specific microRNAs led to accelerated recovery of blood flow, thereby providing a rationale for a novel therapeutic approach.
Consider the title of the study: Inhibition of 14q32 MicroRNAs miR-329, miR-487b, miR-494 and miR-495 Increases Neovascularization and Blood Flow Recovery after Ischemia
Here is a description of ischemia:
ischemia, also spelled as ischaemia or ischæmia[a] (/ɪˈskiːmɪə/), is a restriction in blood supply to tissues, causing a shortage of oxygen and glucose needed for cellular metabolism (to keep tissue alive). Ischemia is generally caused by problems with blood vessels, with resultant damage to or dysfunction of tissue. It also means local anemia in a given part of a body sometimes resulting from congestion (such as vasoconstriction, thrombosis or embolism).
Here are the indications that involve ischemia:
Ischemia is a vascular disease involving an interruption in the arterial blood supply to a tissue, organ, or extremity that, if untreated, can lead to tissue death. It can be caused by embolism, thrombosis of an atherosclerosis artery, or trauma. Venous problems like venous outflow obstruction and low-flow states can cause acute arterial ischemia. An aneurysm is one of the most frequent causes of acute arterial ischemia. Other causes are heart conditions including myocardial infarction, mitral valve disease, chronic atrial fibrillation, cardiomyopathies, and prosthesis, in all of which thrombi are prone to develop.
Now consider the use of GSOs as first line of treatment for ischemia:
Every year about 720,000 Americans have a heart attack. Of these, 515,000 are a first heart attack and 205,000 happen in people who have already had a heart attack.2
Coronary heart disease alone costs the United States $108.9 billion each year.3 This total includes the cost of health care services, medications, and lost productivity.
This market potential is huge. I am currently researching and updating the private message board as I go along. This is transformational information that needs to be digested! All the more reason to stay invested in Idera! When this gets going in the second half of 2015, we should be well above $10 IMO
Agreed. Just took a took--again--at the Idera Leadership team and Board of Directors. Impressive! Of course, there are a lot of smart people in management and on boards in the small-cap biotech world, but to have so many in one place tells you something about the PLACE.